(Yicai) June 25 -- Shares of Fosun Pharmaceutical Group rose after the Chinese drug giant's unit Fosun New Drug inked a deal to fully acquire Henlius Biotech for up to HKD5.4 billion (USD691.7 million) in cash and/or shares. Fosun Pharma [HKG: 2196] jumped 4.5 percent to HKD13.44 (USD1.72) a share as of 10.20 a.m. in Hong Kong today. Its Shanghai-listed stock [SHA: 600196] climbed 1.1 percent to CNY22.16 (USD3.05).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chen Minzhi
News Flash
We sent you a code Enter it below to verify via You'll need a password Make sure it's 8 characters or more SHOW PASSWORD/HIDE PASSWORD Success! Welcome to Yicai Global Find your Yicai Global account Check your email We've sent an email to with a confirmation code. Enter the code below to reset your password. If you don't see the email, check your junk, spam or other folders. Change your password Strong passwords include numbers,letters,and special characters.
News Flash
We sent you a code Enter it below to verify via You'll need a password Make sure it's 8 characters or more SHOW PASSWORD/HIDE PASSWORD Success! Welcome to Yicai Global Find your Yicai Global account Check your email We've sent an email to with a confirmation code. Enter the code below to reset your password. If you don't see the email, check your junk, spam or other folders. Change your password Strong passwords include numbers,letters,and special characters.
Caina’s Shares Plunge After US FDA Places Unit of Chinese Syringe Maker on Import Alert List
(Yicai) April 8 -- Shares of Caina Technology sank after the United States Food and Drug Administration put the Chinese syringe maker on its import alert list over potential device failure. Caina [SHE: 301122] closed down 15.1 percent at CNY22.48 (USD3.11) in Shenzhen today, after earlier plunging by the 20 percent exchange-imposed daily trading limit. The stock has fallen 34 percent so far this year.
Shanghai Pharma Rises After Naming Parent Firm’s VP as New Chair
(Yicai) March 20 -- Shares of Shanghai Pharmaceuticals Holding rose after the leading Chinese drugmaker said it will name the vice president of its parent company as the new chairman. Shanghai Pharma [SHA: 601607] closed 0.3 percent up at CNY17.42 (USD2.42) in Shanghai today. Its Hong Kong-listed stock [HKG: 2607] jumped 3.1 percent to HKD11.98 (USD1.53).
Gas Explosion at Coal Mine in Eastern China Leaves Seven Dead
(Yicai) March 12 -- Seven people have been reported dead so far after a gas explosion caused a coal mine in China’s eastern Anhui province to collapse yesterday. The mine in question is the Xieqiao Coal Mine, which belongs to Huainan Mining Group, the controlling shareholder of Chinese energy giant Huaihe Energy Group, a staffer at Huaihe Energy told Yicai. Rescue efforts are still underway.
Bairun's Shares Sink After China Begins Probe of Cocktail Maker's Chair
(Yicai) Feb. 28 -- Shares of Shanghai Bairun Investment Holding Group tumbled after the maker of flavors, fragrances, and pre-mixed cocktails said Chinese authorities began investigating and detained Chairman and General Manager Liu Xiaodong on suspicion of bribery. Bairun [SHE: 002568] plunged 7.4 percent to CNY20.38 (USD2.83) a share as of 10.50 a.m. in Shenzhen today, after earlier sinking by as much as 8.8 percent.
Mabwell Soars Despite Chinese Biotech Firm Terminates Licensing Deals for Two Cancer Drugs
(Yicai) Feb. 26 -- Shares of Mabwell (Shanghai) Bioscience jumped today despite the Chinese biotechnology company announcing the termination of licensing agreements for two oncology drugs. Mabwell [SHA: 688062] closed 5.3 percent up at CNY29.66 (USD4.12) in Shanghai today.
China Puts Sixth Senior Exec of Shanghai Pharma Under Anti-Graft Investigation
(Yicai) Nov. 22 -- Gu Haoliang, former vice president of Shanghai Pharmaceuticals Holding, is being investigated by an anti-corruption watchdog in the city, making him the firm's sixth senior executive probed in the past six months. Gu is under disciplinary review and supervisory investigation by the Minhang District Commission for Discipline Inspection on suspicion of serious violations of discipline and law, the Shanghai government announced on WeChat late yesterday.
China Puts President of Shanghai Industrial Investment Under Investigation
(Yicai) Nov. 21 -- Zhou Jun, president of Shanghai Industrial Investment Holdings, the biggest state-owned investment holding conglomerate in the city, is being investigated by China's top anti-corruption watchdog on suspicion of severe discipline violations and breaking the law. Zhou is under disciplinary review and supervisory investigation on suspicion of serious violations of law, the Central Commission for Discipline Inspection announced yesterday. On Nov.
China's Brightgene Slumps After CSRC Stops Chairman's Ozempic-Like Weight Loss Boast
(Yicai) Oct. 18 -- Shares of China's Brightgene Bio-Medical Technology plunged after the securities regulator warned the developer of an Ozempic-like weight-loss drug about breaking information disclosure rules due to the chairman's early announcement of losing 15 kilograms of weight due to self-experimenting with the drug candidate. Brightgene [SHA: 688166] closed 3 percent lower at CNY41.79 (USD5.70) today, still almost 90 percent higher since the beginning of this year.
China’s CanSino Says It Won’t Be Impacted by Belcher’s Lawsuit Over Covid-19 Vaccine Deal Termination
(Yicai) March 14 -- CanSino Biologics said that the lawsuit over the termination of a Covid-19 vaccine deal filed by its former Brazilian partner Belcher Farmaceutica will not affect the Chinese drugmaker’s operation and production. CanSino believes it has a strong defense position in the lawsuit as it had already revoked Belcher’s authorization and had not signed any other written agreements with it, the Tianjin-based company noted in a statement late yesterday.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chen
Contact Chen, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack